These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

523 related articles for article (PubMed ID: 34075358)

  • 1. Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort.
    Saxena A; Guttmann A; Masson M; Kim MY; Haberman RH; Castillo R; Scher JU; Deonaraine KK; Engel AJ; Belmont HM; Blazer AD; Buyon JP; Fernandez-Ruiz R; Izmirly PM;
    Lancet Rheumatol; 2021 Aug; 3(8):e585-e594. PubMed ID: 34075358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 seropositivity and subsequent infection risk in healthy young adults: a prospective cohort study.
    Letizia AG; Ge Y; Vangeti S; Goforth C; Weir DL; Kuzmina NA; Balinsky CA; Chen HW; Ewing D; Soares-Schanoski A; George MC; Graham WD; Jones F; Bharaj P; Lizewski RA; Lizewski SE; Marayag J; Marjanovic N; Miller CM; Mofsowitz S; Nair VD; Nunez E; Parent DM; Porter CK; Santa Ana E; Schilling M; Stadlbauer D; Sugiharto VA; Termini M; Sun P; Tracy RP; Krammer F; Bukreyev A; Ramos I; Sealfon SC
    Lancet Respir Med; 2021 Jul; 9(7):712-720. PubMed ID: 33865504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humoral and cellular response in convalescent COVID-19 lupus patients.
    Solé C; Domingo S; Vidal X; Cortés-Hernández J
    Sci Rep; 2022 Aug; 12(1):13787. PubMed ID: 35962159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study.
    Moradi G; Mohamadi Bolbanabad A; Ahmadi S; Aghaei A; Bahrami F; Veysi A; Nasiri Kalmarzi R; Shokri A; Ghaderi E; Mohsenpour B; Mohammadi A
    Int Immunopharmacol; 2021 Sep; 98():107893. PubMed ID: 34174700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Seroprevalence of SARS-CoV-2-specific antibodies and vaccination-related adverse events in systemic lupus erythematosus and rheumatoid arthritis.
    Wang P; Ni J; Chu YY; Chen QQ; Wu GC; Fang Y; Chen C; Zhang RD; Jiang LQ; Zhao Y; Fang X; He J; Wang DG; Wang GH; Pan HF
    Biomed Pharmacother; 2022 Jun; 150():112997. PubMed ID: 35486976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-sectional study evaluating the seroprevalence of SARS-CoV-2 antibodies among healthcare workers and factors associated with exposure during the first wave of the COVID-19 pandemic in New York.
    Bryan A; Tatem K; Diuguid-Gerber J; Cooke C; Romanoff A; Choudhury N; Scanlon M; Kishore P; Sydney E; Masci J; Bakshi P; Pemmasani S; Davis NJ; Maru D
    BMJ Open; 2021 Nov; 11(11):e053158. PubMed ID: 34732494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel (ICoFS): a prospective cohort study.
    Regev-Yochay G; Lustig Y; Joseph G; Gilboa M; Barda N; Gens I; Indenbaum V; Halpern O; Katz-Likvornik S; Levin T; Kanaaneh Y; Asraf K; Amit S; Rubin C; Ziv A; Koren R; Mandelboim M; Tokayer NH; Meltzer L; Doolman R; Mendelson E; Alroy-Preis S; Kreiss Y
    Lancet Microbe; 2023 May; 4(5):e309-e318. PubMed ID: 36963419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Seroprevalence and clinical outcomes of SARS-CoV-2 in paediatric patients with rheumatic disease.
    Walters HM; Mian Z; Thomas L; Cerise J; Eberhard BA; Pagano E; Gottlieb BS; Steigerwald K; Hui-Yuen JS
    Rheumatology (Oxford); 2022 Jun; 61(SI2):SI112-SI119. PubMed ID: 34599820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Systemic Lupus Erythematosus and Immunosuppressive Agents on COVID-19 Vaccination Antibody Response.
    Petri M; Joyce D; Haag K; Fava A; Goldman DW; Zhong D; Xiao S; Milstone A; Magder LS
    Arthritis Care Res (Hoboken); 2023 Sep; 75(9):1878-1885. PubMed ID: 36714913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus neutralising antibody titres after infection, compared by HIV status: a matched case-control observational study.
    Spinelli MA; Lynch KL; Yun C; Glidden DV; Peluso MJ; Henrich TJ; Gandhi M; Brown LB
    Lancet HIV; 2021 Jun; 8(6):e334-e341. PubMed ID: 33933189
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced Humoral Response of SARS-CoV-2 Antibodies following Vaccination in Patients with Inflammatory Rheumatic Diseases-An Interim Report from a Danish Prospective Cohort Study.
    Schreiber K; Graversgaard C; Petersen R; Jakobsen H; Bojesen AB; Krogh NS; Glintborg B; Hetland ML; Hendricks O
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062696
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical performance of four immunoassays for antibodies to SARS-CoV-2, including a prospective analysis for the diagnosis of COVID-19 in a real-life routine care setting.
    Marlet J; Petillon C; Ragot E; Abou El Fattah Y; Guillon A; Marchand Adam S; Lemaignen A; Bernard L; Desoubeaux G; Blasco H; Barin F; Stefic K; Gaudy-Graffin C
    J Clin Virol; 2020 Nov; 132():104633. PubMed ID: 32927357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and analytical evaluation of the Abbott AdviseDx quantitative SARS-CoV-2 IgG assay and comparison with two other serological tests.
    Maine GN; Krishnan SM; Walewski K; Trueman J; Sykes E; Sun Q
    J Immunol Methods; 2022 Apr; 503():113243. PubMed ID: 35181288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence study of SARS-CoV-2 antibodies in healthcare workers following the first wave of the COVID-19 pandemic in a tertiary-level hospital in the south of Ireland.
    Faller E; Wyse A; Barry R; Conlon K; Everard C; Finnegan P; Foran C; Herlihy E; Kerr G; Lapthorne S; McGreal-Bellone A; Morrissey E; O'Sullivan D; O'Sullivan G; Eustace JA; Spillane D; Dempsey C; Benson J; Prentice M; Gallagher J; MacSharry J; Fanning LJ; O'Riordan S; Horgan M; Sadlier C
    BMJ Open; 2021 Jun; 11(6):e051415. PubMed ID: 34103324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 lateral flow IgG seropositivity and serum neutralising antibody responses after primary and booster vaccinations in Chile: a cross-sectional study.
    Sauré D; O'Ryan M; Torres JP; Zuñiga M; Soto-Rifo R; Valiente-Echeverría F; Gaete-Argel A; Neira I; Saavedra V; Acevedo ML; Archila C; Acuña F; Rain M; Basso LJ
    Lancet Microbe; 2023 Mar; 4(3):e149-e158. PubMed ID: 36716754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study.
    Wieske L; van Dam KPJ; Steenhuis M; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; van Ham SM; Kuijpers TW; Rispens T; Eftimov F;
    Lancet Rheumatol; 2022 May; 4(5):e338-e350. PubMed ID: 35317410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. False Positive Results in SARS-CoV-2 Serological Tests for Samples From Patients With Chronic Inflammatory Diseases.
    Kharlamova N; Dunn N; Bedri SK; Jerling S; Almgren M; Faustini F; Gunnarsson I; Rönnelid J; Pullerits R; Gjertsson I; Lundberg K; Månberg A; Pin E; Nilsson P; Hober S; Fink K; Fogdell-Hahn A
    Front Immunol; 2021; 12():666114. PubMed ID: 34012450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.